Vickerman Investment Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-13,575
Closed -$346K 94
2025
Q3
$346K Sell
13,575
-183
-1% -$4.52K 0.07% 70
2025
Q2
$333K Sell
13,758
-37,175
-73% -$867K 0.07% 71
2025
Q1
$1.29M Sell
50,933
-8,787
-15% -$230K 0.29% 52
2024
Q4
$1.58M Sell
59,720
-1,916
-3% -$52K 0.43% 50
2024
Q3
$1.78M Buy
61,636
+438
+0.7% +$12.8K 0.52% 49
2024
Q2
$1.71M Sell
61,198
-651
-1% -$17.9K 0.55% 48
2024
Q1
$1.72M Sell
61,849
-1,160
-2% -$32.2K 0.55% 48
2023
Q4
$1.81M Sell
63,009
-4,896
-7% -$148K 0.62% 45
2023
Q3
$2.25M Buy
67,905
+129
+0.2% +$4.56K 0.92% 44
2023
Q2
$2.49M Buy
67,776
+4,502
+7% +$175K 0.97% 45
2023
Q1
$2.58M Buy
63,274
+2,918
+5% +$126K 1.02% 40
2022
Q4
$3.09M Buy
60,356
+1,789
+3% +$85.8K 1.4% 26
2022
Q3
$2.56M Buy
58,567
+1,867
+3% +$90.7K 1.24% 29
2022
Q2
$2.97M Buy
56,700
+3,250
+6% +$166K 1.41% 23
2022
Q1
$2.62M Buy
53,450
+4,529
+9% +$235K 1.16% 30
2021
Q4
$2.89M Sell
48,921
-9,685
-17% -$480K 1.17% 26
2021
Q3
$2.52M Buy
+58,606
New +$2.6M 1.01% 30

Other funds holding PFE

Vickerman Investment Advisors's PFE Position: Q4 2025 in Review

Vickerman Investment Advisors sold out of Pfizer (PFE) in Q4 2025, closing a stake of 13,575 shares — an estimated $346K sold.

Vickerman Investment Advisors first reported a position in PFE in Q3 2021 and held it in 17 quarters. The position peaked at $3.09M in Q4 2022. 2,915 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Vickerman Investment Advisors reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Vickerman Investment Advisors sold 13,575 Pfizer shares in Q4 2025, an estimated $346K.
  • Vickerman Investment Advisors first reported a position in Pfizer in Q3 2021 and held it in 17 quarters.
  • Vickerman Investment Advisors's Pfizer position peaked at $3.09M in Q4 2022.
  • 2,915 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Vickerman Investment Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.